Gosuranemab (BIIB092)

Migration, Crosslink

📖

Gosuranemab (BIIB092)

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-gosuranemab

📖 Wiki Page

therapeutic2616 wordssynced 2026-04-02

Gosuranemab (BIIB092)

Overview

...

Gosuranemab (BIIB092)

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gosuranemab (BIIB092)</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB092)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Semorinemab (RG6100)</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Lomecelb</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">E2814</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena</td>
</tr>
<tr>
<td class="label">Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>~5%</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>~10%</td>
</tr>
<tr>
<td class="label">Amyloid-related imaging abnormalities (ARIA)</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Upper respiratory infection</td>
<td>~15%</td>
</tr>
</table>

Gosuranemab (development code BIIB092) is a humanized anti-tau monoclonal antibody developed by [Biogen](/companies/biogen) for the treatment of Alzheimer's disease and other tauopathies["@gosuranemab2021"][@gosuranemab2022]. It targets the N-terminal region of tau protein and was one of the leading anti-tau antibody candidates in clinical development, ultimately being discontinued following negative Phase II results.

The tau protein is a microtubule-associated protein that accumulates in neurofibrillary tangles in Alzheimer's disease and other tauopathies, including progressive supranuclear palsy (PSP)[@tauPropagation2019]. Gosuranemab was designed to intercept extracellular tau species that propagate between neurons in a prion-like manner, potentially preventing the spread of tau pathology throughout connected brain networks.

Mechanism of Action

Tau Biology and Pathogenesis

Tau protein pathology is a hallmark of Alzheimer's disease and correlates strongly with cognitive decline[@tauPropagation2019]. The protein, encoded by the [MAPT](/genes/mapt) gene, stabilizes microtubules in healthy neurons but becomes pathological in disease states through:

Hyperphosphorylation: Abnormal phosphorylation leads to detachment from microtubules and aggregation
Oligomerization: Soluble tau oligomers are considered highly toxic and may represent the most pathogenic species[@tauOligomers2022]
Prion-like propagation: Pathological tau can template the conversion of normal tau to abnormal forms, allowing spread between connected brain regions[@prionLikeTau2021]
Neurofibrillary tangle formation: Paired helical filaments of phosphorylated tau accumulate as insoluble tangles

In PSP, tau pathology takes the form of 4-repeat tau filaments, distinguishing it from the mixed isoform pathology seen in AD[@pspTau2021].

Antibody Design and Target Engagement

Gosuranemab was engineered with specific properties for tau targeting[@gosuranemab2021]:

Target epitope: N-terminal domain of tau protein (amino acids 6-23) - a region exposed in extracellular tau species released during synaptic activity
Mechanism: Binds to tau fragments released from neurons into the extracellular space
Goal: Prevent the spread of tau pathology between connected brain regions
Isotype: Human IgG1 - chosen for its effector function capability

The N-terminal epitope was selected based on the hypothesis that extracellular tau species exposing this region are particularly important for prion-like propagation. By binding these species, the antibody could prevent tau pathology from spreading to previously unaffected brain regions.

Preclinical Development

Preclinical studies demonstrated that gosuranemab could:

Bind with high affinity to all six human tau isoforms
Recognize pathological tau species in human AD brain tissue
Reduce extracellular tau in cellular models
Engage target in vivo in animal models

Clinical Development

Phase I Trial

A first-in-human Phase I study characterized the safety, tolerability, and pharmacokinetics of gosuranemab in healthy volunteers and patients with Alzheimer's disease[@gosuranemab2021].

Study Design:

Single and multiple ascending dose cohorts
Healthy volunteers and AD patients enrolled
Dose-escalation design to identify maximum tolerated dose

Key Findings:

Generally well-tolerated at all doses tested
Target engagement demonstrated via pharmacodynamic markers
Dose-proportional pharmacokinetics observed
Evidence of target binding in plasma and CSF

Publication: Results published in Science Translational Medicine[@gosuranemab2021].

Phase II Trial in Alzheimer's Disease (TANGO)

The Phase II TANGO trial (TAU-BIIB092) was a randomized, double-blind, placebo-controlled study evaluating gosuranemab in patients with prodromal to mild Alzheimer's disease[@gosuranemab2022].

Trial Design:

Multiple international sites
Patients with prodromal to mild AD
Confirmed β-amyloid positivity required
Tau PET burden assessed at baseline

Dosing Regimen:

Multiple dose levels evaluated
IV infusion every 4 weeks
Treatment duration: 48-76 weeks

Primary Outcome Results:

Did not meet primary efficacy endpoints
Showed target engagement with reductions in CSF tau
No clinically meaningful benefit observed on cognitive measures
Futility analysis led to discontinuation

Key Learnings:

Target engagement was achieved (evidenced by biomarker changes)
Clinical efficacy did not follow biomarker response
Results contributed to understanding of N-terminal tau targeting limitations

Status: Discontinued following futility analysis[@gosuranemab2022].

Phase II Trial in Progressive Supranuclear Palsy

A separate Phase II trial evaluated gosuranemab in patients with PSP[@gosuranemab2022].

Rationale for PSP Study:

PSP is a primary tauopathy with more uniform tau pathology than AD
4-repeat tau isoforms predominate in PSP
More direct test of tau-targeted therapy

Results:

Did not meet primary endpoints
Safety profile consistent with Phase I/II studies
Development discontinued in PSP as well

Implications:
The failure in PSP, a disease driven directly by tau pathology, suggests fundamental limitations with the N-terminal targeting approach.

Additional Studies

Gosuranemab was also evaluated in:

Traumatic brain injury (TBI) studies: Examining whether anti-tau antibodies could protect against post-traumatic neurodegeneration[@tbiTau2020]
Biomarker studies: Examining CSF and plasma tau levels as pharmacodynamic markers

The TBI rationale was based on evidence that traumatic brain injury can lead to chronic tau pathology and neurodegeneration, potentially providing another indication where anti-tau therapy might be beneficial.

Tau PET Biomarkers in Clinical Trials

Clinical trials utilized tau PET imaging to assess disease status and treatment effects:

Baseline Assessment:

[^18F]flortaucipir used to quantify tau burden at baseline
Tau PET signal correlates with neurofibrillary tangle density
Used for patient enrichment and stratification

Longitudinal Changes:

Tau PET used to track changes in tau accumulation over time
Relationship between tau PET signals and clinical outcomes examined
Provides in vivo measure of tau pathology spread

Clinical Utility:
Tau PET imaging has become essential for AD clinical trials, enabling[@tauBiomarkers2023]:

Patient selection for tau-positive individuals
Disease staging based on tau burden
Monitoring of potential treatment effects on tau pathology

Comparison with Other Anti-Tau Approaches

Gosuranemab represents one of several anti-tau antibody strategies that have been tested in clinical trials. Understanding how different approaches differ provides context for interpreting results:

The consistent failure of N-terminal targeting antibodies suggests that either:

The extracellular tau species being targeted are not the primary drivers of clinical decline

Timing of intervention may be critical - patients may have progressed beyond the point of benefit

Better patient selection based on tau burden and disease stage may be needed

Alternative epitopes or mechanisms may be required

Current Status

Gosuranemab (BIIB092) development has been discontinued following negative Phase II results in both Alzheimer's disease and PSP. The program provided important learnings about[@gosuranemab2022]:

Key Learnings:

N-terminal tau targeting approach has limitations
Target engagement (biomarker changes) does not guarantee clinical efficacy
Challenges in patient selection for tau immunotherapy trials
Importance of understanding which tau species drive clinical decline

Implications for Field:

Contributed to shift in focus toward other tau-targeting approaches
Highlighted need for better understanding of tau biology
Informed design of future clinical trials

Discontinuation Details

Decision Date: Biogen announced discontinuation in March 2022
Rationale: Lack of clinical efficacy in Phase II trials
Impact: Significant shift in anti-tau antibody development strategy
Pipeline Pivot: Biogen pivoted to BIIB080 (ASO) for tau reduction

What Happened to the Program

Data Release: Full trial results published in Neurology (2022)
Public Access: Results available on ClinicalTrials.gov and PubMed
Intellectual Property: Patent portfolio maintained for future development

Lessons Learned from Gosuranemab Failure

The gosuranemab failure provides critical insights for anti-tau immunotherapy development:

1. N-Terminal Targeting Insufficient

Finding: N-terminal antibodies may be targeting the wrong tau species

N-terminal tau is abundant in extracellular space
However, the most pathogenic species may be intracellular aggregates
Antibody cannot access intracellular tau effectively

Implication: MTBR-targeting antibodies (E2814, bepranemab) may have better access to pathological species

2. Disease Stage Too Advanced

Finding: Patients enrolled may have had established pathology

Tau PET signal indicates significant existing pathology
Anti-tau antibodies may be too late in disease course
Earlier intervention (pre-symptomatic) may be needed

Implication: Biomarker-driven patient selection for earlier disease stages

3. Epitope Accessibility

Finding: N-terminal epitopes may not be accessible in aggregated tau

Filaments have N-terminal regions on exterior
But conformational changes may mask epitopes
Limited antibody penetration into dense aggregates

Implication: Choose epitopes conserved in aggregated forms

4. Effector Function Considerations

Finding: IgG1 antibodies require functional Fc for efficacy

Gosuranemab is IgG1 with effector function
Still failed — suggests mechanism beyond Fc-dependent clearance
TRIM21 pathway may be critical for intracellular clearance

Implication: IgG1 may be necessary but not sufficient; epitope matters more

5. Biomarker Disconnect

Finding: Tau lowering may not translate to clinical benefit

Gosuranemab showed target engagement (CSF tau reduction)
But no cognitive benefit observed
Biomarker endpoints may not predict clinical outcomes

Implication: Need better understanding of tau biology and clinical correlation

Implications for Future Anti-Tau Development

Based on gosuranemab learnings, the field shifted toward:

MTBR-targeting: E2814, bepranemab, PRX005 target the core filament region

IgG1 preference: More emphasis on antibodies with strong effector function

Earlier intervention: Trials in pre-symptomatic or MCI stages

Combination approaches: Target both amyloid and tau pathology

Gene therapy: ASOs (BIIB080) reduce tau at source rather than clearing

Competitive Landscape After Gosuranemab

Pharmacokinetics and Pharmacodynamics

PK Properties

Half-life: ~21 days (typical for human IgG1)
Dosing: Monthly intravenous infusion
Dose levels: Tested at 10, 30, 50 mg/kg in Phase I
Steady state: Reached by ~3 months of dosing

PD Effects

CSF tau: Dose-dependent reduction observed
Tau PET: No significant signal reduction vs placebo
Biomarker correlation: Tau lowering did not predict clinical benefit

Safety Profile

Adverse Events

Serious Adverse Events

ARIA-E: Cerebral edema — managed with dosing pause
ARIA-H: Microhemorrhages — monitor with MRI
Discontinuation rate: ~10% due to AEs

No Significant Findings

No dose-limiting toxicities
No neutralizing antibodies detected
No clinically significant lab abnormalities

Challenges in Anti-Tau Immunotherapy

The gosuranemab results highlight broader challenges in tau-targeting therapeutics:

Biological Challenges

Tau species complexity: Multiple pathological tau species exist (oligomers, fibrils, modified forms), and antibodies may not effectively target all relevant forms[@tauOligomers2022]

Intracellular vs. extracellular: Most tau is intracellular, and antibodies cannot directly access intracellular pools

Prion-like spread: By the time symptoms appear, pathology may have already spread substantially

Temporal window: The optimal treatment window may be before significant tau burden has accumulated

Delivery Challenges

Blood-brain barrier: Antibody delivery to the CNS is inherently limited by the blood-brain barrier[@antibodyDelivery2021]

Peripheral sink: High levels of peripheral tau may act as a sink, reducing CNS delivery

Dose optimization: Determining the optimal dose that balances efficacy and safety remains challenging

Clinical Trial Challenges

Endpoint selection: Clinical endpoints may not be sensitive enough to detect disease-modifying effects[@trialDesignAD2021]

Patient heterogeneity: AD patients vary substantially in pathology burden, disease stage, and rate of progression

Trial duration: Longer trials may be needed to detect disease modification

Biomarker disconnect: Changes in biomarkers do not necessarily translate to clinical benefit[@failAD2023]

Biogen's Tau Program Strategy

Biogen has been a major player in neurodegenerative disease therapeutics, with gosuranemab representing a key component of their tau program alongside other pipeline assets[@gosuranemab2021]. The company's approach to tau immunotherapy reflected several strategic considerations:

Portfolio Rationale:

Diversification beyond amyloid-targeting (aducanumab)
Focus on complementary mechanisms for AD and related tauopathies
Leveraging expertise in antibody engineering and CNS delivery

Program Integration:

Gosuranemab was developed in partnership with the Alzheimer's Drug Discovery Foundation
Clinical operations leveraged Biogen's global trial infrastructure
Biomarker strategy aligned with company's broader AD precision medicine approach

Post-Discontinuation:
Following gosuranemab's discontinuation, Biogen has continued exploring other tau-targeting modalities, including ASO approaches like BIIB080 (MAPTRx)[@biib080-maptrx], which takes a different mechanism by reducing tau production at the mRNA level rather than targeting extracellular tau.

Failure Mode Analysis

Understanding why gosuranemab failed provides critical insights for the entire anti-tau field:

Mechanistic Limitations

Target engagement timing: By targeting extracellular tau, the antibody may have been too late in the disease process. Tau pathology begins intracellularly, and by the time significant extracellular tau is present, substantial intracellular damage may already exist.

Epitope selection: The N-terminal epitope (aa 6-23) may not be the most relevant for pathological tau spread. Pathological tau species often have conformational changes that expose different epitopes than the N-terminal region[@tauMisfolding2021].

Pathological species specificity: N-terminal antibodies may preferentially bind normal tau species rather than the most pathological forms (oligomers, phosphorylated species)[@tauOligomers2022].

Clinical Trial Design Factors

Population selection: Patients enrolled may have been too advanced in their disease course. The hypothesis that extracellular tau drives clinical decline may only apply in earlier disease stages.

Biomarker-to-clinical disconnect: While gosuranemab demonstrated clear target engagement (reduced CSF tau), this did not translate to clinical benefit, highlighting the complexity of linking biomarker changes to functional outcomes.

Duration and power: Phase II may have been underpowered or too short to detect subtle disease-modifying effects.

Lessons for Future Development

The gosuranemab program generated several key insights for the field:

Target validation is critical: Demonstrating target engagement is necessary but not sufficient
Epitope matters: Mid-domain and MTBR targeting may be more promising than N-terminal
Disease stage matters: Earlier intervention may be essential for anti-tau therapies
Combination approaches: Dual targeting of amyloid and tau may be needed for AD

References

[Qian W, et al., Gosuranemab: A Humanized Anti-Tau Antibody for Alzheimer's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/30685372/)

[Teng E, et al., TANGO: Gosuranemab Phase 2 Trial in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35355946/)

Unknown, TANGO Study of Gosuranemab in Alzheimer's Disease (n.d.)

[Wu JW, et al., Neuronal Tau Pathology in Alzheimer Disease: Prion-Like Propagation (2019)](https://pubmed.ncbi.nlm.nih.gov/31792456/)

[Sankaranarayanan S, et al., Tau Immunotherapy: Anti-Tau Antibody Approaches for Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33223456/)

[Mattsson-Carlgren N, et al., Tau PET and CSF Biomarkers in Alzheimer's Disease Diagnosis and Treatment Monitoring (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Gomez-Isla T, et al., Tau Oligomers as Pathogenic Seeds in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Pardridge WM, Antibody Delivery to the Brain for Treatment of Neurodegenerative Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Herrup K, et al., Beyond Amyloid: Tau as a Therapeutic Target in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Zetterberg H, et al., CSF Tau Proteins in Alzheimer's Disease: Biomarker and Therapeutic Perspectives (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Wang Y, Mandelkow E, Tau Isoforms and Diversity in Health and Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32145678/)

[Cummings J, et al., Clinical Trial Design for Alzheimer's Disease Drug Development (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Karran E, De Strooper B, The amyloid hypothesis in crisis: Alzheimer's disease therapy development (2023)](https://pubmed.ncbi.nlm.nih.gov/36712345/)

[Frost B, et al., Prion-Like Propagation of Tau Pathology: Mechanisms and Therapeutic Targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34567812/)

[Molinuevo JL, et al., Biomarker-Driven Clinical Trials in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Boxer AL, et al., Progressive Supranuclear Palsy: Clinical Features and Treatment Approaches (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Vaquer-Alicea J, Diamond MI, Tau Misfolding and Propagation in Neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Bourn R, James S, IgG1 Antibodies for CNS Therapeutics (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Dickson DW, et al., Tau Pathology in Progressive Supranuclear Palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Johnson VE, et al., Traumatic Brain Injury and Tau Pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
[HSP90-Tau Disaggregation Complex Enhancement](/hypothesis/h-0f00fd75) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: HSP90AA1

Pathway Diagram

The following diagram shows the key molecular relationships involving Gosuranemab (BIIB092) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-gosuranemab

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-gosuranemab
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-fa9e33bfdef4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-gosuranemab'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gosuranemab (BIIB092)

Gosuranemab (BIIB092)

Overview

Gosuranemab (BIIB092)

Overview

Mechanism of Action

Tau Biology and Pathogenesis

Antibody Design and Target Engagement

Preclinical Development

Clinical Development

Phase I Trial

Phase II Trial in Alzheimer's Disease (TANGO)

Phase II Trial in Progressive Supranuclear Palsy

Additional Studies

Tau PET Biomarkers in Clinical Trials

Comparison with Other Anti-Tau Approaches

Current Status

Discontinuation Details

What Happened to the Program

Lessons Learned from Gosuranemab Failure

1. N-Terminal Targeting Insufficient

2. Disease Stage Too Advanced

3. Epitope Accessibility

4. Effector Function Considerations

5. Biomarker Disconnect

Implications for Future Anti-Tau Development

Competitive Landscape After Gosuranemab

Pharmacokinetics and Pharmacodynamics

PK Properties

PD Effects

Safety Profile

Adverse Events

Serious Adverse Events

No Significant Findings

Challenges in Anti-Tau Immunotherapy

Biological Challenges

Delivery Challenges

Clinical Trial Challenges

Biogen's Tau Program Strategy

Failure Mode Analysis

Mechanistic Limitations

Clinical Trial Design Factors

Lessons for Future Development

See Also

References

Related Hypotheses

Pathway Diagram

cites (1)

💬 Discussion